Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement

被引:59
作者
Khalaj-Hedayati, Atin [1 ]
Chua, Caroline Lin Lin [1 ]
Smooker, Peter [2 ]
Lee, Khai Wooi [1 ]
机构
[1] Taylors Univ, Fac Hlth & Med Sci, Sch Biosci, 1 Jalan Taylors, Subang Jaya 47500, Selangor, Malaysia
[2] RMIT Univ, Sch Sci, Dept Biosci & Food Technol, Victoria, Australia
关键词
immunogenicity; influenza vaccine; nanoparticles; subunit vaccine; vaccine delivery; VIRUS-LIKE PARTICLES; MODIFIED PLGA NANOPARTICLES; IMPROVED CROSS-PROTECTION; MATRIX M(TM) ADJUVANT; H1N1; 2009; VACCINE; IMMUNE-RESPONSES; H5N1; BACILLUS-SUBTILIS; DELIVERY-SYSTEM; SAFETY;
D O I
10.1111/irv.12697
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The threat of novel influenza infections has sparked research efforts to develop subunit vaccines that can induce a more broadly protective immunity by targeting selected regions of the virus. In general, subunit vaccines are safer but may be less immunogenic than whole cell inactivated or live attenuated vaccines. Hence, novel adjuvants that boost immunogenicity are increasingly needed as we move toward the era of modern vaccines. In addition, targeting, delivery, and display of the selected antigens on the surface of professional antigen-presenting cells are also important in vaccine design and development. The use of nanosized particles can be one of the strategies to enhance immunogenicity as they can be efficiently recognized by antigen-presenting cells. They can act as both immunopotentiators and delivery system for the selected antigens. This review will discuss on the applications, advantages, limitations, and types of nanoparticles (NPs) used in the preparation of influenza subunit vaccine candidates to enhance humoral and cellular immune responses.
引用
收藏
页码:92 / 101
页数:10
相关论文
共 115 条
  • [21] Bacterial spores as vaccine vehicles
    Duc, L
    Hong, HA
    Fairweather, N
    Ricca, E
    Cutting, SM
    [J]. INFECTION AND IMMUNITY, 2003, 71 (05) : 2810 - 2818
  • [22] Preferential uptake of chitosan-coated PLGA nanoparticles by primary human antigen presenting cells
    Duran, Veronica
    Yasar, Hanzey
    Becker, Jennifer
    Thiyagarajan, Durairaj
    Loretz, Brigitta
    Kalinke, Ulrich
    Lehr, Claus-Michael
    [J]. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2019, 21
  • [23] FDA, 2011, CONS WHETH FDA REG P
  • [24] Bacillus subtilis as a tool for vaccine development:: from antigen factories to delivery vectors
    Ferreira, LCS
    Ferreira, RCC
    Schumann, W
    [J]. ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS, 2005, 77 (01): : 113 - 124
  • [25] Structure function relationships of immunostimulatory polysaccharides: A review
    Ferreira, Sonia S.
    Passos, Claudia P.
    Madureira, Pedro
    Vilanova, Manuel
    Coimbra, Manuel A.
    [J]. CARBOHYDRATE POLYMERS, 2015, 132 : 378 - 396
  • [26] A Recombinant Viruslike Particle Influenza A (H7N9) Vaccine
    Fries, Louis F.
    Smith, Gale E.
    Glenn, Gregory M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (26) : 2564 - 2566
  • [27] Taxonomy of the genus Bacillus and related genera:: The aerobic endospore-forming bacteria
    Fritze, D
    [J]. PHYTOPATHOLOGY, 2004, 94 (11) : 1245 - 1248
  • [28] Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge
    Gao, Xiao
    Wang, WenJuan
    Li, YuFeng
    Zhang, ShaoGeng
    Duan, YueQiang
    Xing, Li
    Zhao, ZhongPeng
    Zhang, PeiRui
    Li, ZhiWei
    Li, RuiSheng
    Wang, Xiliang
    Yang, PengHui
    [J]. ANTIVIRAL RESEARCH, 2013, 98 (01) : 4 - 11
  • [29] Active targeting of dendritic cells with mannan-decorated PLGA nanoparticles
    Ghotbi, Zahra
    Haddadi, Azita
    Hamdy, Samar
    Hung, Ryan W.
    Samuel, John
    Lavasanifar, Afsaneh
    [J]. JOURNAL OF DRUG TARGETING, 2011, 19 (04) : 281 - 292
  • [30] Virus-like particles: Passport to immune recognition
    Grgacic, Elizabeth V. L.
    Anderson, David A.
    [J]. METHODS, 2006, 40 (01) : 60 - 65